Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Category

Sub-category

Conference

Cost comparison of IV vs subcutaneous trastuzumab in HER2+ breast cancer in...

Dr Kunvar Harsh Upveja - Biocon Biologics, Bengaluru, India

Cost comparison of IV vs subcutaneous trastuzumab in HER2+ breast cancer in Morocco ( Dr Kunvar Harsh Upveja - Biocon Biologics, Bengaluru, India )

Disparities in mammogram screening amongst LGBTQ+ populations

Dr Manas Pustake - Texas Tech University Health Science Center, El Paso, USA

Disparities in mammogram screening amongst LGBTQ+ populations ( Dr Manas Pustake - Texas Tech University Health Science Center, El Paso, USA )

AI improves accuracy in identifying HER2-low and HER2-ultralow breast cancers

Dr Marina De Brot - A.C. Camargo Cancer Center, São Paulo, Brazil

AI improves accuracy in identifying HER2-low and HER2-ultralow breast cancers ( Dr Marina De Brot - A.C. Camargo Cancer Center, São Paulo, Brazil )

Trastuzumab deruxtecan plus pertuzumab may delay cancer growth for some HER2...

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA

Trastuzumab deruxtecan plus pertuzumab may delay cancer growth for some HER2-positive advanced breast cancers ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )

HER2-positive breast cancer: Predicting pCR from clinicopathologic variables...

Dr Nadine M Tung - Beth Israel Deaconess Medical Center, Boston, USA

HER2-positive breast cancer: Predicting pCR from clinicopathologic variables and genomic testing ( Dr Nadine M Tung - Beth Israel Deaconess Medical Center, Boston, USA )

Oral paclitaxel shows non-inferior efficacy compared to IV paclitaxel for HER2...

Prof Sung-Bae Kim - Asan Medical Center, Seoul, South Korea

Oral paclitaxel shows non-inferior efficacy compared to IV paclitaxel for HER2-negative mBC ( Prof Sung-Bae Kim - Asan Medical Center, Seoul, South Korea )

CtDNA monitoring of ER+/HER2- breast cancer during adjuvant endocrine therapy...

Dr Lajos Pusztai - Yale School of Medicine, New Haven, USA

CtDNA monitoring of ER+/HER2- breast cancer during adjuvant endocrine therapy shows promise ( Dr Lajos Pusztai - Yale School of Medicine, New Haven, USA )

Vepdegestrant could extend PFS for some ESR1-mutated advanced breast cancers

Dr Erika P Hamilton - Sarah Cannon Research Institute, Nashville, USA

Vepdegestrant could extend PFS for some ESR1-mutated advanced breast cancers ( Dr Erika P Hamilton - Sarah Cannon Research Institute, Nashville, USA )

Olaparib boosts chemotherapy’s impact on BRCA-mutated breast cancer

Dr Jean Abraham - University of Cambridge, Cambridge, UK

Olaparib boosts chemotherapy’s impact on BRCA-mutated breast cancer ( Dr Jean Abraham - University of Cambridge, Cambridge, UK )

Intraoperative radiotherapy: The Medical City experience

Dr Angeli Andrea Cocos-Alcantara - The Medical City, Pasig, Philippines

Intraoperative radiotherapy: The Medical City experience ( Dr Angeli Andrea Cocos-Alcantara - The Medical City, Pasig, Philippines )

The added value of integrative medicine

Dr Marta Capelan, Dr Beth DuPree and Rosa Olmos

The added value of integrative medicine ( Dr Marta Capelan, Dr Beth DuPree and Rosa Olmos )

Boost IORT in breast cancer: Peruvian experience

Dr Gustavo Sarria - INEN, Lima, Peru

Boost IORT in breast cancer: Peruvian experience ( Dr Gustavo Sarria - INEN, Lima, Peru )

More from ecancer